Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bachem Holding AGBCHMF 91 EV-to-EBITDA is 27.79 as of Jul. 22, 2026, which is 2% above its 10-year median of 27.35. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $99.13 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 398 Biotechnology companies, Bachem Holding AG ranks worse than 72.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bachem Holding AG's enterprise value is $7,070.8 Mil.
Bachem Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $254.5 Mil. Therefore, Bachem Holding AG's EV-to-EBITDA for today is 27.79.
The historical rank and industry rank for Bachem Holding AG's EV-to-EBITDA or its related term are showing as below:
BCHMF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 17.51 Med: 27.35 Max: 99.84
Current: 25.64
During the past 13 years, the highest EV-to-EBITDA of Bachem Holding AG was 99.84. The lowest was 17.51. And the median was 27.35.
BCHMF's EV-to-EBITDA is ranked worse than 72.86% of 398
companies
in the Biotechnology industry
Industry Median: 12.295
vs BCHMF: 25.64
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Bachem Holding AG (OTCPK:BCHMF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bachem Holding AG's PE Ratio (TTM) for today is calculated as:
Bachem Holding AG's share price for today is $87.34.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bachem Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.468.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bachem Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCHMF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Bachem Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's EV-to-EBITDA falls into.
Bachem Holding AG's current Enterprise Value is $7,070.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bachem Holding AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $254.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG (BCHMF) has a EV-to-EBITDA of 27.79 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bachem Holding AG. This is near median its historical median of 27.35. Over the past decade, Bachem Holding AG's EV-to-EBITDA has ranged from 17.51 to 99.84. According to the industry distribution chart, Bachem Holding AG ranks #290 out of 398 companies in the Biotechnology industry, placing it in the top 72.9%.
Is Bachem Holding AG's EV-to-EBITDA too high?
Bachem Holding AG's current EV-to-EBITDA of 27.79 is near median its 10-year median of 27.35. Over the past 10 years, this metric has ranged from a low of 17.51 to a high of 99.84. The Biotechnology industry median EV-to-EBITDA is 12.30. Bachem Holding AG's value of 27.79 is 126% above this industry median. Based on the distribution chart, Bachem Holding AG ranks #290 out of 398 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #290 out of 398 companies for EV-to-EBITDA. This places Bachem Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 12.30. Bachem Holding AG's value of 27.79 is 126% above this benchmark. Historically, Bachem Holding AG's own EV-to-EBITDA has ranged from 17.51 to 99.84 over the past decade. While the company's 10-year median is 27.35 vs. the industry median of 12.30, Bachem Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.30, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current EV-to-EBITDA of 27.79 is 126% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bachem Holding AG. For the Biotechnology industry, the median EV-to-EBITDA is 12.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current EV-to-EBITDA is 27.79, which is near median its own 10-year median of 27.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $99.13, compared to a current price of $87.34 — trading 11.9% below its estimated fair value. The current EV-to-EBITDA is 27.79, which is near median its 10-year median of 27.35 and 126% above the Biotechnology industry median of 12.30. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current EV-to-EBITDA is 27.79 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 11.9% below its estimated GF Value™ of $99.13.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
EV-to-EBITDA: 27.79 (near median its 10-year median of 27.35)
GF Value™: $99.13 vs. price of $87.34 (11.9% below fair value)
Industry Position: 126% above the Biotechnology median (#290 of 398)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
